CFO VoiceCFO Tribune ↗

Speaker · REGN

Christopher Fenimore

Executive Vice President, Finance and Chief Financial Officer of Regeneron, Regeneron Pharmaceuticals, as the company printed it. 3 quotes on the record, from July 30, 2026 to October 30, 2026.

On CFO Tribune: Christopher Fenimore's CFO record · who holds Regeneron Pharmaceuticals's CFO seat

Quotes, newest first

We are pleased with our third quarter financial results, which marked our third consecutive quarter of double-digit growth in both revenue and non-GAAP EPS
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron, Regeneron PharmaceuticalsRegeneron Reports Third Quarter 2026 Financial and Operating Results · October 30, 2026 · source: sec.gov · permalink
Second quarter revenues grew 17% and non-GAAP net income per share grew 11%, marking our second consecutive quarter of double-digit growth on both measures
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron, Regeneron PharmaceuticalsRegeneron Reports Second Quarter 2026 Financial and Operating Results · July 30, 2026 · source: sec.gov · permalink
By the end of the second quarter, we had fully repaid the Sanofi Development Balance, which represented the outstanding amount due to Sanofi for their funding of prior collaboration development activities.
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron, Regeneron PharmaceuticalsRegeneron Reports Second Quarter 2026 Financial and Operating Results · July 30, 2026 · source: sec.gov · permalink

These are the quotes CFO Voice has verified, not everything Christopher Fenimore has said. We publish each as the company released it and add no view on the company's results or shares. Spot an error? Send a correction.